Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sten Stovall

London, UK
Sten Stovall is a London-based editor and writer with 40 years of experience in the field of journalism, including more than 20 years with Reuters and eight years with The Wall Street Journal/Dow Jones Newswires. He also has wide radio and television reporting experience and a solid network of contacts in the biopharma world. Sten is part of our team of specialist reporters, generating insightful features and analysis about R&D, product development, regulatory issues and industry trends for publications such as "The Pink Sheet", Scrip and IN VIVO.
Advertisement
Set Alert for Articles By Sten Stovall

Latest From Sten Stovall

Sensyne Health CEO Drayson Says IPO Will See AI Group To Profitability

Flush with IPO funding, AI-focused healthcare technology group Sensyne Health will now ready additional products and find three more NHS trust partnerships. CEO Lord Drayson spoke to Scrip.

Artificial Intelligence Business Strategies

Stand-Off: Vertex Refuses NICE Data on CF Drug Symkevi, HTA Body Awaits Next Move

Vertex says it will not file data on its cystic fibrosis drug Symkevi (tezacaftor/ivacaftor) until the UK's NICE changes the way it assesses drugs.

Approvals Commercial

With Novo Nordisk Dependent On GLP-1s, Even Perceived Price Pressures Can Hurt

Long-term top-line market forecasts for Novo Nordisk are heavily reliant on its GLP-1 portfolio's potential - so pricing uncertainties, especially in the US,  can unnerve sentiment, as seen when it reported Q2 results.

Commercial Companies

Seeking Efficiencies, Novo Nordisk To Squeeze Costs, Boost Growth Drivers

Novo Nordisk aims to offset US pricing pressures with increased cost management, freeing investment for key growth drivers like Ozempic and oral Semaglutide.

Commercial Companies

Allergan And Editas Sharpen Their CRISPR Focus On Ocular Drugs

Allergan and CRISPR specialist Editas have reinforced their gene editing R&D pact launched in March 2017.

Commercial Companies

Arix Taps Australia's 'Undervalued' Pharmaxis As First VIPE, More Planned

UK-listed Arix completed its first Venture Investment in Public Equity (VIPE), leading a A$24m (£13.4m) investment in Australian biotech Pharmaxis.

Financing Business Strategies
See All
Advertisement
UsernamePublicRestriction

Register